According to recently released research from the National Institute for Occupational Health and Safety, or NIOSH - an arm of the U.S. Centers for Disease Control (CDC) - Maine has the nation's highest death rate from mesothelioma.
The CDC describes mesothelioma as a fatal cancer primarily associated with exposure to asbestos, a naturally occurring mineral found in rock formations. The latency period between exposure and clinical manifestations of the disease, or recognizable symptoms and subsequent diagnosis, is commonly 20 to 40 years, though it may be longer.
Mesothelioma, which attacks the mesothelial linings in the lungs and abdomen, is the result of miniscule asbestos fibers that, when inhaled or ingested, irritate mesothelial tissues. This irritation, or inflammation, leads to mesothelioma, which has no known cure. Most patients die within a year to 18 months of diagnosis.
Before 1970, asbestos was used in a wide range of products, from insulation to floor tiles, tile adhesives, acoustical ceiling tiles, plaster and acoustical or insulative sprays on walls or ceilings.
Asbestos is no longer mined in the United States, and manufacturing processes limit it to one percent or less under 1989 U.S. Environmental Protection Agency rulings, but imported products still contain asbestos in unregulated amounts.
Because of this failure to regulate, the CDC estimates that 1.3 million construction and industrial workers are currently being exposed to potentially lethal asbestos. This is in addition to the millions of workers already exposed. CDC calculates that, between 1999 and 2005, 18,068 individuals died from mesothelioma, with the rate remaining relatively stable at about 14.1 individuals per million per year.
Maine's rate, on the other hand, stands at 27.5 individuals per million during the same period. This is the highest death rate from mesothelioma in the entire country. Second in mortality was Wyoming, with 22.2 deaths per million, followed by West Virginia with 21; Pennsylvania with 20.8; New Jersey with 20.2; and Washington with 20.1. Males accounted for more than 80 percent of those deaths, and Caucasians for more than 95 percent.
From 2000 to 2004, two counties - Sagadahoc in Maine, and Koochiching in Minnesota - had age-adjusted malignant mesothelioma death rates that exceeded the national average by 500 percent. During that same period, nearly 20 percent of victims were female, and more than 30 percent lived in one of five states: California, Florida, New York, Pennsylvania, and Texas.
Construction work accounts for 15 percent of mesothelioma deaths. Other venues with a high rate of mesothelioma include ship (and boat) building and repair, chemical manufacturing, petroleum refining, and the utility industry. Trades or occupations most at risk include pipefitters, steamfitters, plumbers, mechanical engineers, electricians and elementary school teachers.
Mesothelioma commonly strikes older individuals. For example, there were only 311 deaths in the under-45 age group during the 1999-2005 period, but 8,858 deaths among those 75 and older. Thanks to legislation and increasing oversight during demolition of older buildings, mesothelioma deaths are expected to peak next year and then gradually decline to pre-1999 levels.
According to NIOSH, Maine's higher rate of mesothelioma is due to the state's smaller population, blue-collar worker-based economy, and the large number of purpose-built older buildings which were rehabbed for additional use (as residences, for example) rather than being demolished.
Ki Moon Bang, a senior epidemiologist for NIOSH, speaking to Maine Public Broadcasting, noted that, historically, Maine employers like textile mills, paper mills and ship builders used significant amounts of asbestos in structures that date from the early 1900s or earlier. To make his point, Bang cited the Bath Iron Works shipyard, located on the Kennebec River in Bath, Maine and built in 1826.
Source
Monday, July 27, 2009
Monday, July 20, 2009
Mesothelioma and Early Lung Cancer Identified by Screening
Using computed tomography scans to screen former asbestos workers can detect both early and late-stage lung cancer and late-stage mesothelioma, according to a study in the May Journal of Thoracic Oncology. However, it’s still not clear whether screening for these cancers might improve patients’ prognoses.
Exposure to asbestos fibers is a known risk factor for lung cancer and the cause of mesothelioma. Although asbestos is still not completely banned in the U.S., it was phased out of American industry to a large degree beginning in the 1970s. However because asbestos-related diseases can take 20 to 40 years to emerge after people have been exposed, former asbestos workers and those exposed to products containing this carcinogen continue to be diagnosed with asbestos caused cancers.
As researchers search for better treatments and even a cure for these diseases, they are also focusing on new diagnostic methods that might identify the cancers earlier. Early diagnosis is particularly crucial with mesothelioma, because many patients survive only one year after they first start to show signs, and symptoms are often difficult to distinguish from those of other lung diseases.
One potential screening method uses low-dose computed tomography (LDCT) to evaluate the lungs and their lining (pleura). LDCT can locate plaques in the lungs, which are a sign of asbestos exposure and have been linked to an increased cancer risk.
Currently, there are no recommendations about using LDCT or any other method to screen people who have been exposed to asbestos, and screening isn’t routinely done. “There are currently no methods for the early detection of mesothelioma available,” says lead author Heidi Roberts, MD, Associate Professor of Radiology at the University of Toronto. “This is why we are doing the research.”
To determine the effectiveness of LDCT as a screening tool for asbestos-related lung cancers, Dr. Roberts and her colleagues recruited 516 people (most of them men) who had been exposed to asbestos at least 20 years before, or who had known plaques. Participants were given LDCT scans of the chest. Patients who had abnormal scans were given follow-up tests. Those with normal test results were invited to have an annual LDCT scan.
Of the 516 participants, 357 had evidence of plaques. Based on the results of the first scan and annual scans, six of the patients were diagnosed with lung cancers and four were diagnosed with mesothelioma.
Although LDCT was able to detect advanced mesothelioma, as well as early- and late-stage lung cancers, it was not able to diagnose early mesothelioma. The study authors say they need to continue screening patients to help them get a better idea of what early mesothelioma looks like. Also, they say adding biomarkers (substances in the blood that indicate the presence of cancer) to the screening process may provide greater sensitivity to help diagnose those at very high risk for mesothelioma.
Even as techniques are fine-tuned, screening is just one step of a three-tiered effort to combat these cancers, according to Dr. Roberts. “The second step is the parallel development of biomarkers, and the third step is the parallel development of treatment strategies,” she says. “These have to be developed hand-in-hand in order to make this a useful and meaningful tool.”
Source
Exposure to asbestos fibers is a known risk factor for lung cancer and the cause of mesothelioma. Although asbestos is still not completely banned in the U.S., it was phased out of American industry to a large degree beginning in the 1970s. However because asbestos-related diseases can take 20 to 40 years to emerge after people have been exposed, former asbestos workers and those exposed to products containing this carcinogen continue to be diagnosed with asbestos caused cancers.
As researchers search for better treatments and even a cure for these diseases, they are also focusing on new diagnostic methods that might identify the cancers earlier. Early diagnosis is particularly crucial with mesothelioma, because many patients survive only one year after they first start to show signs, and symptoms are often difficult to distinguish from those of other lung diseases.
One potential screening method uses low-dose computed tomography (LDCT) to evaluate the lungs and their lining (pleura). LDCT can locate plaques in the lungs, which are a sign of asbestos exposure and have been linked to an increased cancer risk.
Currently, there are no recommendations about using LDCT or any other method to screen people who have been exposed to asbestos, and screening isn’t routinely done. “There are currently no methods for the early detection of mesothelioma available,” says lead author Heidi Roberts, MD, Associate Professor of Radiology at the University of Toronto. “This is why we are doing the research.”
To determine the effectiveness of LDCT as a screening tool for asbestos-related lung cancers, Dr. Roberts and her colleagues recruited 516 people (most of them men) who had been exposed to asbestos at least 20 years before, or who had known plaques. Participants were given LDCT scans of the chest. Patients who had abnormal scans were given follow-up tests. Those with normal test results were invited to have an annual LDCT scan.
Of the 516 participants, 357 had evidence of plaques. Based on the results of the first scan and annual scans, six of the patients were diagnosed with lung cancers and four were diagnosed with mesothelioma.
Although LDCT was able to detect advanced mesothelioma, as well as early- and late-stage lung cancers, it was not able to diagnose early mesothelioma. The study authors say they need to continue screening patients to help them get a better idea of what early mesothelioma looks like. Also, they say adding biomarkers (substances in the blood that indicate the presence of cancer) to the screening process may provide greater sensitivity to help diagnose those at very high risk for mesothelioma.
Even as techniques are fine-tuned, screening is just one step of a three-tiered effort to combat these cancers, according to Dr. Roberts. “The second step is the parallel development of biomarkers, and the third step is the parallel development of treatment strategies,” she says. “These have to be developed hand-in-hand in order to make this a useful and meaningful tool.”
Source
Monday, July 13, 2009
Surgery portion of new mesothelioma treatment plan found effective
Pleurectomy/decortication, a type of surgery involving the removal of the outermost lining surrounding the lungs, was assessed in a study presented at the 2009 European Multidisciplinary Conference in Thoracic Oncology.
A particular kind of surgery performed as a part of a treatment plan intended for patients with malignant mesothelioma was considered successful preceding chemotherapy treatment in a study presented May 3 at the 2009 European Multidisciplinary Conference in Thoracic Oncology.
The surgical method known as a pleurectomy/decortication (a type of surgery involving the removal of the outermost lining surrounding the lungs) was assessed in the study. The study observed the procedure in combination with chemotherapy and radiation in a three-fold treatment approach.
A group of experts, including Dr. Servet Bölükbas and Dr. Horst Schmidt Kliniken, devised the study to check the efficiency of pleurectomy/decortication as the surgical component in malignant pleural mesothelioma treatment rather than pneumonectomy (removal of a lung).
Malignant mesothelioma is a rare cancer caused almost exclusively by asbestos exposure. Patients usually exhibit mesothelioma symptoms several decades following initial exposure, permitting the cancer to progress to later developmental stages. A multimodal therapy method using two or more methods of treatment is frequently suggested for mesothelioma patients.
Thirty-five patients with malignant pleural mesothelioma were enrolled in the study over a five-year period from November 2002 through October 2007. Patients underwent the pleurectomy/decortications procedure prior to four chemotherapy sessions (using cisplatin and pemetrexed) and radiation to the chest wall and mediastinum (a group of structures in the thorax) roughly four to six weeks following the surgery. Approximately 94 percent of the patients finished the treatment regimen.
The one year survival rate was 75 percent with a median survival rate of 33.2 months. The two year survival rate was 61 percent with the three year survival rate reported at 43 percent.
The researchers concluded that the use of pleurectomy/decortication as the surgical component in a multimodal treatment plan using chemotherapy and radiation demonstrated positive survival results and morbidity calls for extra testing.
Source
A particular kind of surgery performed as a part of a treatment plan intended for patients with malignant mesothelioma was considered successful preceding chemotherapy treatment in a study presented May 3 at the 2009 European Multidisciplinary Conference in Thoracic Oncology.
The surgical method known as a pleurectomy/decortication (a type of surgery involving the removal of the outermost lining surrounding the lungs) was assessed in the study. The study observed the procedure in combination with chemotherapy and radiation in a three-fold treatment approach.
A group of experts, including Dr. Servet Bölükbas and Dr. Horst Schmidt Kliniken, devised the study to check the efficiency of pleurectomy/decortication as the surgical component in malignant pleural mesothelioma treatment rather than pneumonectomy (removal of a lung).
Malignant mesothelioma is a rare cancer caused almost exclusively by asbestos exposure. Patients usually exhibit mesothelioma symptoms several decades following initial exposure, permitting the cancer to progress to later developmental stages. A multimodal therapy method using two or more methods of treatment is frequently suggested for mesothelioma patients.
Thirty-five patients with malignant pleural mesothelioma were enrolled in the study over a five-year period from November 2002 through October 2007. Patients underwent the pleurectomy/decortications procedure prior to four chemotherapy sessions (using cisplatin and pemetrexed) and radiation to the chest wall and mediastinum (a group of structures in the thorax) roughly four to six weeks following the surgery. Approximately 94 percent of the patients finished the treatment regimen.
The one year survival rate was 75 percent with a median survival rate of 33.2 months. The two year survival rate was 61 percent with the three year survival rate reported at 43 percent.
The researchers concluded that the use of pleurectomy/decortication as the surgical component in a multimodal treatment plan using chemotherapy and radiation demonstrated positive survival results and morbidity calls for extra testing.
Source
Monday, July 6, 2009
Mesothelioma Treatment Option Found Effective
A treatment option for mesothelioma cancer patients has recently been evaluated at a European medical conference. A surgical procedure known as a pleurectomy/decortication, which involves the removal of the outermost lining of the lungs, is intended for patients suffering from malignant mesothelioma.
According to a study presented at the 2009 European Multidisciplinary Conference in Thoracic Oncology, the surgery was considered successful when it preceded chemotherapy treatment and was used as part of a three-fold treatment approach along with radiation therapy.
The study was devised by a group of mesothelioma treatment experts to validate the efficiency of the pleurectomy/decortication procedure another type of surgery: pneumonectomy, the medical term for the removal of a lung.
Malignant mesothelioma is a rare cancer caused almost exclusively by asbestos exposure. Due to a long latency period, patients often develop mesothelioma symptoms several decades after the initial exposure.
Mesothelioma patients are often advised by doctors to undertake multiple forms of treatment at once in order to have the highest chance of survival. One popular treatment combination involves Alimta, a type of chemotherapy, following resectable surgery.
For this study, thirty-five patients with malignant pleural mesothelioma were observed over a five-year period from November 2002 through October 2007. Patients underwent the pleurectomy/decortications procedure prior to four chemotherapy sessions and radiation to the chest wall and thorax.
Approximately 94 percent of the patients finished the treatment regimen. The one year survival rate was 75 percent, the two year survival rate was 61 percent, and the three year survival rate reported at 43 percent.
The researchers believe that further study is needed, but pleurectomy/decortication did demonstrate positive survival results. Here in the United States, leading oncologists, such as Dr. Carrie Redlich of Yale University, are working to find a cure for this devastating disease.
Source
According to a study presented at the 2009 European Multidisciplinary Conference in Thoracic Oncology, the surgery was considered successful when it preceded chemotherapy treatment and was used as part of a three-fold treatment approach along with radiation therapy.
The study was devised by a group of mesothelioma treatment experts to validate the efficiency of the pleurectomy/decortication procedure another type of surgery: pneumonectomy, the medical term for the removal of a lung.
Malignant mesothelioma is a rare cancer caused almost exclusively by asbestos exposure. Due to a long latency period, patients often develop mesothelioma symptoms several decades after the initial exposure.
Mesothelioma patients are often advised by doctors to undertake multiple forms of treatment at once in order to have the highest chance of survival. One popular treatment combination involves Alimta, a type of chemotherapy, following resectable surgery.
For this study, thirty-five patients with malignant pleural mesothelioma were observed over a five-year period from November 2002 through October 2007. Patients underwent the pleurectomy/decortications procedure prior to four chemotherapy sessions and radiation to the chest wall and thorax.
Approximately 94 percent of the patients finished the treatment regimen. The one year survival rate was 75 percent, the two year survival rate was 61 percent, and the three year survival rate reported at 43 percent.
The researchers believe that further study is needed, but pleurectomy/decortication did demonstrate positive survival results. Here in the United States, leading oncologists, such as Dr. Carrie Redlich of Yale University, are working to find a cure for this devastating disease.
Source
Subscribe to:
Comments (Atom)